Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Carcinoma, Hepatocellular 121Carcinoma, Renal Cell 60Neoplasms 43Liver Neoplasms 42Neoplasm Metastasis 23Carcinoma, Non-Small-Cell Lung 21Leukemia, Myeloid, Acute 20Melanoma 18Kidney Neoplasms 16Breast Neoplasms 16Brain Neoplasms 13Pancreatic Neoplasms 12Sarcoma 11Prostatic Neoplasms 10Glioblastoma 10Lung Neoplasms 9Thyroid Neoplasms 8Recurrence 8Rectal Neoplasms 8Colorectal Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Colonic Neoplasms 7Stomach Neoplasms 6Ovarian Neoplasms 6Multiple Myeloma 6Leukemia 6Gliosarcoma 6Carcinoma 6Unspecified Adult Solid Tumor, Protocol Specific 5Urinary Bladder Neoplasms 4

Interventions

fludarabine phosphate 17Mycophenolic Acid 14Cyclophosphamide 14Whole-Body Irradiation 13Tacrolimus 11Peripheral Blood Stem Cell Transplantation 11Antilymphocyte Serum 11Busulfan 9Methotrexate 8Melphalan 7Filgrastim 7Cyclosporine 7Methylprednisolone 6thymoglobulin 5Stem Cell Transplantation 5Radiotherapy 5Thiotepa 4Cytarabine 4Antibodies 4fludarabine 3Transplantation 3Psychiatric Rehabilitation 3Isotretinoin 3Granulocyte Colony-Stimulating Factor 3Flow Cytometry 3Etoposide 3Cord Blood Stem Cell Transplantation 3Clofarabine 3Azacitidine 3Alemtuzumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Myelomonocytic, Juvenile × Sorafenib × Clear all
NCT01445080 2021-02-02

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
70 enrolled 26 charts
LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡